Levi & Korsinsky, LLP announces that a NTRA class action lawsuit has been filed on behalf of investors who purchased Natera, Inc. (NTRA) common stock between February 26, 2020 and April 19, 2022. For more on the NTRA Lawsuit please contact us today.
According to the Natera, Inc. lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s non-invasive prenatal test, Panorama, was not reliable and resulted in high rates of false positives; (2) the Company’s screening test for kidney transplant failure, Prospera, did not have superior precision compared to competing tests; (3) as a result of defendants’ false and misleading claims about Natera’s technology, the Company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, defendants’ statements about the company’s business, operations, and prospects lacked a reasonable basis.
If you suffered a loss in Natera, Inc. you have until June 27, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.